SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-10 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction of incorpora ...

As of November 5, 2021, the registrant had 65,576,334 shares of common stock, par value $0.01 per share outstanding. PREDICTIVE ONCOLOGY INC. TABLE OF CONTENTS | | Page No. | | --- | --- | | PART I. FINANCIAL INFORMATION | | | Item 1. Unaudited Condensed Consolidated Financial Statements | 3 | | Condensed Consolidated Balance Sheets as of September 30, 2021, and December 31, 2020 | 3 | | Condensed Consolidated Statements of Net Loss for the three and nine months ended September 30, 2021, and | | | September ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-100 ...

(Mark One) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33-1007393 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 2915 Commers Drive, Suite 900 | Eagan, Minnesota 55121 | (Address of principal executive offices) (Zip Code) 651-389-4800 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction (IRS Employer of incorporation o ...

Predictive Oncology Inc. (NASDAQ:POAI) Q2 2019 Results Earnings Conference Call August 19, 2019 5:30 PM ET Company Participants Scott Gordon - IR, CORE IR Carl Schwartz - President and CEO Bob Myers - CFO Gerald Vardzel - President of Helomics Amelia Warner - COO of Helomics Conference Call Participants Jason Kolbert - Dawson James Operator Good afternoon, and welcome to the Predictive Oncology Earnings Conference Call for the Second Quarter Ending June 30, 2019. All participants will be in a listen-only mo ...

Precision Therapeutics Inc. (AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE IR Carl Schwartz - President and Chief Executive Officer Bob Myers - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to the Precision Therapeutics Earnings Conference Call for the First Quarter Ended March 31, 2019. All participants will be in a listen-only mode. [Operator Instructions] Participants of this call are ...

Financial Data and Key Metrics Changes - Revenue for 2018 was $1,412,000, a 116% increase from $655,000 in 2017, driven by the sale of 41 STREAMWAY systems and increased disposable supplies [15] - Cost of sales increased to $416,000 in 2018 from $148,000 in 2017, with expectations that costs will decline as a percentage of revenue due to volume discount purchasing agreements [16] - Gross profit margin decreased slightly to 71% in 2018 from 77% in 2017, attributed to assistance with installation costs for customers [16] - Operating expenses rose to $8,900,000 in 2018 from $6,600,000 in 2017, including extraordinary expenses related to acquisitions and startup costs [17] Business Line Data and Key Metrics Changes - Skyline Medical had record sales in 2018, expanding its sales efforts both nationally and internationally, with machines now present in five of the world's seven continents [6][7] - TumorGenesis was formed to develop rapid testing methods for ovarian tumors, with contracts signed for biomarker screening kits [9][10] - The acquisition of Helomics Corporation is expected to enhance the company's capabilities in artificial intelligence for women's cancer [11] Market Data and Key Metrics Changes - The company has established a European office and signed independent distributors in various regions, including Canada, Europe, the Middle East, and Asia [6][7] - The database of tumors at Helomics is significant, with over 150,000 tumors, which the company aims to monetize through collaborations and data sharing agreements [11][22] Company Strategy and Development Direction - The company aims to become a leading artificial intelligence entity focused on women's cancer, leveraging its extensive tumor database and deep learning software [11] - Future collaborations and partnerships are anticipated to enhance the database and accelerate revenue growth [20][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting income levels from Helomics to rise dramatically due to collaborations [20] - The company is preparing to raise additional funds, with a current cash position of about $1 million and a burn rate of approximately $440,000 per month for Skyline Medical [25] Other Important Information - The company is in the process of finalizing the acquisition of Helomics, which is expected to be completed shortly [8] - The new Generation 3 machine is set for testing in May 2019, with plans for a commercial release thereafter [8] Q&A Session Summary Question: How is the company addressing the shortfall in Helomics' earnings? - Management acknowledged the initial disappointment but expressed confidence in the collaborations that are expected to boost income levels significantly [20] Question: What is the current state of the tumor database and its monetization potential? - The database is in good shape, but sequencing is still in progress, which is necessary for monetization [22][23] Question: What is the current cash position and burn rate? - The company has about $1 million in cash, with a burn rate of $440,000 per month for Skyline Medical and $300,000 for Helomics [25] Question: When can shareholders expect to see value from the Advisory Board? - Management expects to see progress from the Advisory Board within the next three to six months following the merger completion [34]